Does Empagliflozin And Linagliptin Interact with Lithium?
CDI records a moderate classification for Empagliflozin And Linagliptin and Lithium. The stored summary is: SGLT2 inhibitor component may decrease serum lithium concentrations. Monitor lithium levels more frequently during initiation and dosage changes. The mechanism involves decreased serum lithium concentrations. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Empagliflozin And Linagliptin Class
- Dipeptidyl Peptidase 4 Inhibitor
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Decreased serum lithium concentrations
What To Tell Your Doctor or Pharmacist
If you are taking Empagliflozin And Linagliptin and your doctor is considering prescribing Lithium (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider